News | June 13, 2014

Cardinal Health Ships 2 Millionth Mynx Vascular Closure Device

Company celebrates milestone after recent acquisition of AccessClosure

Mynx Vascular Closure Device Cardinal Health 2 Millionth Shipment June 2014

June 13, 2014 — Cardinal Health announced the 2 millionth shipment of the Mynx Vascular Closure Device (VCD). The Mynx product family of vascular closure devices combines the reliability of an easy-to-use deployment system with the security of mechanical closure and the safety of an extravascular sealant that enables physicians to seal an arteriotomy securely without leaving anything permanently behind in the artery.

“There are several vascular closure devices on the market, but most of them leave material behind, either inside the femoral artery, like a plug, or material in the arterial wall, like a suture or clip, which limits their use in certain situations,” said Najam Wasty, director of invasive cardiovascular laboratory and director of Interventional Cardiology Fellowship Training Program at a major teaching institution. “The major advantage of the Mynx VCD is that it is extravascular. In other words, it does not leave any materials permanently inside the artery or in the wall of the artery. Many physicians find this feature attractive since it allows safe use of the Mynx VCD in most situations.”

The first Mynx Vascular Closure Device received U.S. Food and Drug Administration (FDA) approval in May 2007. The Mynx product family includes the new Mynx Ace Vascular Closure Device, launched in 2013 in the United States, and the MynxGrip Vascular Closure Device, launched in 2012. Mynx devices use proprietary Grip Technology, which employs an extravascular sealant that actively adheres to the artery for safe and secure mechanical closure and dissolves within 30 days, leaving nothing permanently behind in the healed artery.  

Cardinal Health completed its acquisition of AccessClosure in May.

The Mynx product family is clinically proven and has been featured in several peer-reviewed articles.

For more information: www.accessclosure.com


Related Content

News | Vascular Closure Devices

September 16, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced that Dr. Magnus ...

Home September 16, 2022
Home
News | Vascular Closure Devices

November 9, 2021 — Results from the largest randomized trial available comparing different closure device strategies ...

Home November 09, 2021
Home
News | Vascular Closure Devices

July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully ...

Home July 15, 2021
Home
News | Vascular Closure Devices

August 17, 2020 — Veryan Medical announced it will support Vasorum in the commercialization of the Celt atrial closure ...

Home August 17, 2020
Home
Videos | Vascular Closure Devices

Ashish Pershad, M.D., chief of interventional cardiology, Banner University Medical Center, Phoenix, explains the trend ...

Home October 17, 2019
Home
Technology | Vascular Closure Devices

April 3, 2019 — Essential Medical Inc. received U.S. Food and Drug Administration (FDA) clearance for its large bore ...

Home April 03, 2019
Home
Technology | Vascular Closure Devices

December 20, 2018 — Cardiva Medical Inc. announced the company has received premarket approval (PMA) from the U.S. Food ...

Home December 20, 2018
Home
News | Vascular Closure Devices

November 21, 2018 – Vivasure Medical Ltd. recently announced the European launch of the PerQseal closure device for ...

Home November 21, 2018
Home
News | Vascular Closure Devices

November 12, 2018 — The Vascade MVP vascular closure system met its endpoints compared to manual compression in a ...

Home November 11, 2018
Home
Technology | Vascular Closure Devices

November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S. launch of Mynx Control Vascular Closure ...

Home November 05, 2018
Home
Subscribe Now